- Brodalumab was associated with sustained improvements in clinical symptoms and QoL with no new safety signals at 5 years in a phase 2 open-label extension (OLE) study.
- 77.3% of patients maintained a static Physician’s Global Assessment score of ≤1 at week 240.
- A ≥75% improvement in the Psoriasis Area and Severity Index was maintained for >80% of patients during weeks 4-264.
- Mean improvement in PASI was 92.1% at week 240, whereas mean improvement in body surface area affected was 92.8%.
- Dermatology Life Quality Index score was 0 or 1 for >67% of patients during weeks 4-264.
- 97.8% of patients experienced treatment-emergent adverse events (TEAEs); grade ≥3 AEs were reported in 22.7% of patients.
- 181 patients who completed a 2-week, phase 2 trial received brodalumab 210 mg every 2 weeks.
- Funding: Ortho Dermatologics.
- No comparator group.
- Potential selection bias.